JACC: Cardiooncology

Papers
(The median citation count of JACC: Cardiooncology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Addressing the Overlooked124
The Pursuit of “Best” Anticoagulant for Cancer-Associated Thrombosis117
Driven by Impact, Not Impact Factor107
Full Issue PDF104
Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions99
Preventing Cancer Therapy–Related Cardiotoxicity88
Atrial Fibrillation in Patients With Cancer85
LAAO in Cardio-Oncology81
Full Issue PDF80
Editorial Board78
Determining Cause-Specific Mortality in Cancer Survivors60
Editorial Board60
JACC: CardioOncology53
Editorial Board50
Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms50
Editorial Board45
Heart Failure Post-Hematopoietic Cell Transplantation in Patients With Lymphoma45
Clinical Practice Guidelines in Cardio-Oncology45
How to Treat Breast Cancer After Childhood Cancer44
Embracing the Power of the Polysocial Risk Score43
Takotsubo Cardiomyopathy Associated With Checkpoint Inhibitor Therapy43
Understanding and Reducing the Social and Environmental Determinants of Health Disparities in Cardio-Oncology42
Performance Status and Long-Term Outcomes in Cancer-Associated Pulmonary Embolism42
PULMONARY VASCULAR TOXICITY WITH TYROSINE KINASE INHIBITOR THERAPY: A RARE CASE IN A CHRONIC MYELOID LEUKEMIA PATIENT41
Delayed Diagnosis and Recovery of Fulminant Immune Checkpoint Inhibitor-Associated Myocarditis on VA-ECMO Support40
PALLIATIVE RESECTION OF A CARDIAC SARCOMA40
Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome40
PREVALENCE OF IMPAIRED CARDIORESPIRATORY FITNESS & ITS CONTRIBUTORS IN LUNG CANCER PATIENTS PRIOR TO RADIOTHERAPY40
Outcomes of Surgery in Cardiac Angiosarcoma38
Cardiac Surveillance in Immune Checkpoint Inhibitor Therapy38
Reply33
Cardio-Oncology and Health Equity32
Editorial Board/Officers Page32
Full Issue PDF31
Imaging-Based Obesity Assessment for Risk Factor Stratification and Prognostication in Malignancy30
Full Issue PDF30
How to Treat Diffuse Large B-Cell Lymphoma29
Full Issue PDF29
Could Clonal Hematopoiesis Explain the Link Between Increased Cancer Mortality Incidence in Heart Failure?28
Leveraging Population Genomics to Enhance Preventive Cardio-Oncology27
The Cause of Death in Patients With Cancer27
Navigating the Uncharted26
Cardiovascular Safety in Oncology Clinical Trials26
Editorial Board/ACC Officers Page24
Cardiac Magnetic Resonance in Cardio-Oncology23
To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy22
Chest Pain in Cancer Patients21
Premature Cardiac Senescence21
Increased Cardiac Risk After a Second Malignant Neoplasm Among Childhood Cancer Survivors19
(Less) Time and Energy19
ER-Specific Autophagy or ER-Phagy in Cardiac Myocytes Protects the Heart Against Doxorubicin-Induced Cardiotoxicity19
Health Literacy, Individual and Community Engagement, and Cardiovascular Risks and Disparities19
Guiding Treatment With Recovered CTRCD18
Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy18
Concomitant Administration of Dantrolene is Sufficient to Protect Against Doxorubicin-Induced Cardiomyopathy18
Atherosclerotic Cardiovascular Diseases Are Associated With Incident Metastatic and Nonmetastatic Cancer17
Heart Transplantation in Adriamycin-Associated Cardiomyopathy in the Contemporary Era of Advanced Heart Failure Therapies17
LAG3 Blockade Expands T Cells Within Atherosclerotic Plaque17
Adding a Rock to a Hard Place17
Time-Restricted Eating to Reduce Cardiovascular Risk Among Older Breast Cancer Survivors16
Inclusion of Exercise in Cancer Treatment Planning16
The Rise and Fall of C-Reactive Protein15
Cardiovascular Considerations During Cancer Therapy15
Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer15
Hormonal Therapy and Cardiovascular Health15
Is Preventative Oophorectomy Safe?14
Probing the Anthracycline-Induced Myocardial Injury14
Cardiac Tumors and Innovations in Local Therapies14
Reply14
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part14
Epidemiology and Antithrombotic Therapy for Cancer-Associated Arterial Thromboembolism in Japan14
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes14
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies13
Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer13
Physician Knowledge and Awareness About Cardiac Amyloidosis in the Middle East and Gulf Region13
FATAL TRIAD OF IMMUNE CHECKPOINT INHIBITOR THERAPY13
How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer13
Management of Amyloid Cardiomyopathy in Resource-Constrained Settings13
Epigenomics of Cardio-Oncology12
Use of Polygenic Risk Score for Prediction of Heart Failure in Cancer Survivors12
Reply12
Priorities in Cardio-Oncology12
Reply12
How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk12
Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors12
Considerations of Competing Risks Analysis in Cardio-Oncology Studies12
Balancing Promise and Evidence12
The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer12
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction11
Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes11
Impact of Age at Diagnosis on Cardiotoxicity in High-Grade Osteosarcoma and Ewing Sarcoma Patients11
Arterial Thromboembolism in Cancer Patients11
Endothelin Receptor Blocker Reverses Breast Cancer–Induced Cardiac Remodeling11
Intracardiac Ultrasound and Mapping Integration-Guided Endomyocardial Biopsy for the Diagnosis of Myocardial Melanoma Metastasis11
Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity11
Severe vs Nonsevere Immune Checkpoint Inhibitor-Induced Myocarditis10
Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients10
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity10
Raise the Flag9
Reply9
How to Perform Pericardiocentesis in Cancer Patients With Thrombocytopenia9
When Clot Is Tumor9
Beyond Mean Heart Dose9
Clinical Phenotype and Prognostic Significance of Frailty in Transthyretin Cardiac Amyloidosis9
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients9
Can We Estimate Cardiorespiratory Fitness in Breast Cancer Survivors Without Exercise?9
Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitor Trials8
Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis8
Progress in Cardiac Imaging Uncovers the Epidemiology of Wild-Type Transthyretin Amyloid Cardiomyopathy8
Withdrawal of Neurohormonal Antagonists in Breast Cancer Patients With Cardiotoxicity and Improved Left Ventricular Function8
Withdrawal of Cardioprotective Therapy in Patients With Recovered Cancer Therapy–Related Cardiac Dysfunction8
Full Issue PDF8
Cardiotoxicity of BRAF/MEK Inhibitors8
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology8
Severe Aortic Stenosis and Chronic Myeloid Leukemia8
Unveiling the Mechanisms of Anthracycline Cardiotoxicity8
How Common Is Pre-Existing Cardiovascular Disease in Cancer Patients7
Reply7
Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapy7
The ESC Cardio-Oncology Guidelines7
Cardio-Oncology Care Delivery for All Patients With Cancer Within Academic and Community Settings7
Thank You to Our Community and to Our Peer Reviewers7
Cardiovascular Toxicity During Advanced Prostate Cancer Treatment7
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients7
Cardio-Oncology in Iran7
Full Issue PDF7
Cardiovascular Disease Among Patients With AML and CHIP-Related Mutations7
Cardiac Risk Stratification Before Lung Cancer Radiation7
Association of Cardiometabolic Disease With Cancer in the Community7
Full Issue PDF7
Cancer Survivors and Cardiovascular Risk: What Patients Should Know From the Perspective of Another Survivor7
The ESC 2022 Cardio-Oncology Guidelines and the Road Ahead in Cardio-Oncology7
Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy6
Achieving Optimal Cardiovascular Health6
Prostate Cancer and Cardiovascular Risk Factors6
Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure6
Reply6
Direct Oral Anticoagulants in Patients With Cancer and Nonvalvular Atrial Fibrillation6
Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy–Related Cardiac Dysfunction6
Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies6
ELECTROPHYSIOLOGIC PROPERTIES OF HEART BLOCK INDUCED BY IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS FROM CEMIPLIMAB6
Amyloid Cardiomyopathy6
The Impact of the Cancer Moonshot on Cardio-Oncology Science6
High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population6
Full Issue PDF6
Full Issue PDF6
Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients5
Cardio-Oncology and Our Community5
TYROSINE KINASE INHIBITOR ASSOCIATED POLYMORPHIC VENTRICULAR TACHYCARDIA5
ASYMPTOMATIC CARDIAC METASTASIS OF NEUROENDOCRINE TUMOR DIAGNOSED BY PET CT SCAN5
Cardiovascular Disease Related to Immune Therapy5
Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy5
Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy5
CARDIAC, MUSCULAR, AND NEUROLOGICAL TOXICITY SECONDARY TO PEMBROLIZUMAB IN A PATIENT WITH MELANOMA5
Editorial Board5
Fulminant Cardiotoxicity in a Patient With Cardiac Lymphoma Treated With CAR-T Cells5
Clinical, Echocardiographic, and Biomarker Associations With Impaired Cardiorespiratory Fitness Early After HER2-Targeted Breast Cancer Therapy5
Transcatheter Compared With Surgical Aortic Valve Replacement in Patients With Previous Chest-Directed Radiation Therapy5
Title Page5
Moving the Pendulum for Earlier Detection of Systolic and Diastolic Dysfunction in Cancer Survivors5
Improving Long-term Outcomes in ATTR-CM5
Editorial Board/Officers Page4
Association of Cardiac Substructure Radiation Dose With Arrhythmia4
Prediction of Coronary Heart Disease Events in Blood or Marrow Transplantation Recipients4
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis4
Extensive Cardiac Function Analyses Using Contemporary Echocardiography in Childhood Cancer Survivors4
SGLT2 Inhibitors in Mitigating Cancer Therapy-Related Cardiac Dysfunction4
Cardiovascular Risk in Prostate Cancer4
Cardiac Benign Metastatic Leiomyoma4
Frailty4
Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer4
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma4
Reply4
Elucidating the Signal from the Noise4
Enhancing Life’s Essential 8 for Cardiovascular Risk Assessment in Breast Cancer Survivors4
Full Issue PDF4
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy4
A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors4
Learning From Trials4
Assessing Neurohormonal Antagonist Withdrawal in HER2+ Breast Cancer Patients With CTRCD4
Prevalence of Cardiovascular Disease in Patients With Potentially Curable Malignancies3
Full Issue PDF3
Monitoring Tafamidis, The Most Expensive Cardiac Medication3
Cancer Prevention and Early Detection in Patients With Cardiovascular Disease3
Cardiovascular Disease and Breast Cancer3
ESC Cardio-Oncology Guidelines3
Reply3
Uncontrolled Cardiovascular Risk Factors in Prostate Cancer Patients3
ATTR Cardiomyopathy Meets Multiple Myeloma3
Screening for Coronary Artery Disease in Cancer Survivors3
Overcoming LGBTQI+ Disparities in Cardio-Oncology3
Reply3
Assessing STEMI Outcomes in Patients With Cancer3
Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer3
Full Issue PDF3
Predicting Left Ventricular Dysfunction in Childhood Cancer Survivors3
Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category3
ATTR Amyloidosis: Current and Emerging Management Strategies3
Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer3
Incorporating Exercise Training into Cardio-Oncology Care3
Associations Between Social Determinants of Health and Cardiovascular Health of U.S. Adult Cancer Survivors3
My Hope for Cardio-Oncology3
Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy3
Cancer Diagnosis, Physical Activity, and Heart Disease Risk3
Immune Checkpoint Inhibitors in Cardiac Sarcoma3
Reply3
How to Treat Adult Acute Myeloid Leukemia3
Electrophysiological Manifestations of Cardiac Amyloidosis3
Cardiac Amyloidosis3
Anthracycline Cardiotoxicity in Adult Cancer Patients3
Cardiovascular Health Equity for Survivors of Childhood Cancer2
The Evolving Epidemiology of Amyloidosis2
PANCREATIC CANCER WITH METASTASIS, LYMPHANGITIC CARCINOMATOSIS AND PULMONARY VEIN INVASION - WHEN IT RAINS IT POURS!2
Full Issue PDF2
PROPORTIONATE AND ABSOLUTE PULMONARY EMBOLISM MORTALITY IN ONCOLOGY IN THE UNITED STATES FROM 1999-20192
FIRST DOSE ORTHOSTATIC HYPOTENSION FOLLOWING DOCETAXEL AND GEMCITABINE INFUSION2
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients2
Anticoagulation and Arterial Thrombotic Events in Ambulatory Patients With Cancer2
Editorial Board2
Risk for Myocardial Infarction Following 5-Fluorouracil Treatment in Patients With Gastrointestinal Cancer2
Cardiovascular Considerations Before Cancer Therapy2
Tumor Genetics Are Thrombogenic2
How to Treat Renal Cell Carcinoma2
Understanding Race, Genotype, and Socioeconomic Status in Transthyretin Amyloid Cardiomyopathy2
RIGHT VENTRICULAR PRIMARY CARDIAC LYMPHOMA DIAGNOSED WITH CARDIAC MRI2
Acknowledgments2
The Potential Impact of the 2022 ESC Cardio-Oncology Guidelines on Clinical Practice in China2
Editorial Board2
Toward a More Precise Understanding of Obesity and Cancer and Cardiovascular Disease Risk2
Aging, Aortic Stenosis, and Transthyretin Cardiac Amyloidosis2
Tracing the Pathways From Cardiovascular Disease to Cancer2
Correction2
Atorvastatin Does Not Attenuate Aortic Stiffening After Doxorubicin for Breast Cancer and Lymphoma (PREVENT-WF-98213)2
Interpreting Nonrandomized Evidence for Clinical Decision Making in Cardio-Oncology2
Straining for More Evidence2
CARDIOVASCULAR DISEASE RISK CONTROL IN SURVIVORSHIP: THE ROLE AND IMPLEMENTATION OF CARDIO-ONCOLOGY SERVICES2
Impaired Cardiorespiratory Fitness in Cancer Survivors2
ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity2
Growing, Building, and Defining the Field of Cardio-Oncology for Our Patients2
Medical Management of Hemodynamically Unstable Sinoatrial Node Dysfunction in a Patient With Intracardiac Lymphoma2
Editorial Board/Officers Page2
How to Manage Cisplatin-Based Chemotherapy–Related Cardiovascular Disease in Patients With Testicular Cancer1
Early Tracking of Radiation-Induced Cardiotoxicity1
Validity of Estimated Cardiorespiratory Fitness in Patients With Primary Breast Cancer1
Permissive Cardiotoxicity1
Self-Reported Physical Activity, QoL, Cardiac Function, and Cardiorespiratory Fitness in Women With HER2+ Breast Cancer1
Editorial Board1
Genomic Screening for Pathogenic Transthyretin Variants Finds Evidence of Underdiagnosed Amyloid Cardiomyopathy From Health Records1
Early Diagnosis of Amyloid Cardiomyopathy1
Leveling Up1
0.25462603569031